{"entity":{"id":"nct04966663","kind":"trial","name":"Using ctDNA to Determine Therapies for Lung Cancer","aka":["ctDNA Lung RCT"],"tldr":"A phase 2 trial of nivolumab, pemetrexed, gemcitabine, cisplatin and other drugs in lung cancer, run by University Health Network, Toronto, now recruiting.","summary":"Using ctDNA to Determine Therapies for Lung Cancer is a phase 2, randomised interventional study registered as NCT04966663 by University Health Network, Toronto, with a registry enrolment figure of 66 participants, started 2022-03-28 and due to reach its primary completion in 2026-08-01. Interventions recorded: Nivolumab; Pemetrexed; Gemcitabine; Cisplatin; Carboplatin; ctDNA blood test. Conditions listed: Non Small Cell Lung Cancer; Complete Surgical Resection; Circulating Tumor DNA. Primary outcome: Relapse Free Survival. Lung eligibility wording from the registry: \"Complete surgical resection of T1-2N0M0 NSCLC or T3/T4 multifocal NSCLC\". Sites: Canada. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT04966663","url":"https://clinicaltrials.gov/study/NCT04966663"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":["checkpoint-inhibitor","cytotoxic-chemotherapy","mrd-testing","platinum"],"targets":[],"drugs":["nivolumab","pemetrexed","gemcitabine","cisplatin","carboplatin"],"companies":["bms"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04966663","phase":"2","setting":"From Liquid Biopsy to Cure: Using ctDNA Detection of Minimal Residual Disease to Identify Patients for Curative Therapy After Lung Cancer Resection","sponsor":"University Health Network, Toronto","enrolled":66,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04966663/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"mrd-testing","kind":"technology","name":"MRD / molecular residual disease testing","route":"/technologies/mrd-testing/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"}],"drug":[{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"cisplatin","kind":"drug","name":"Cisplatin","route":"/drugs/cisplatin/"},{"id":"gemcitabine","kind":"drug","name":"Gemcitabine","route":"/drugs/gemcitabine/"},{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"},{"id":"pemetrexed","kind":"drug","name":"Pemetrexed","route":"/drugs/pemetrexed/"}],"company":[{"id":"bms","kind":"company","name":"Bristol Myers Squibb","route":"/companies/bms/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}